Jiangsu Nanfang Medical Co., Ltd. (SHA:603880)
China · Delayed Price · Currency is CNY 9.87
+0.15 (1.54%)
Sep 14, 2026, 3:00 PM CST
Jiangsu Nanfang Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 564.57 | 599.72 | 602.01 | 599.66 | 544.78 | 523.74 |
Other Revenue | 0.71 | 0.79 | 0.6 | 0.43 | 0.59 | 3.7 |
| 565.28 | 600.51 | 602.62 | 600.1 | 545.37 | 527.44 | |
Revenue Growth | -6.84% | -0.35% | 0.42% | 10.04% | 3.40% | -50.82% |
Cost of Revenue | 554.08 | 586.22 | 631.53 | 566.33 | 477.73 | 432.92 |
Gross Profit | 11.21 | 14.29 | -28.91 | 33.76 | 67.63 | 94.52 |
Selling, General & Admin | 50.92 | 50.88 | 94.79 | 59.95 | 56.17 | 70.97 |
Research & Development | 26.27 | 28.61 | 28.72 | 28.18 | 27.73 | 30.62 |
Other Operating Expenses | 5.5 | 5.87 | 5.16 | 6.52 | 5.66 | 4.35 |
Operating Expenses | 93.14 | 95.04 | 112.14 | 124.54 | 93.99 | 110.53 |
Operating Income | -81.94 | -80.75 | -141.05 | -90.77 | -26.36 | -16.01 |
Interest Expense | -8.43 | -21.73 | -26.43 | -23.19 | -20.18 | -11.8 |
Interest & Investment Income | 9.53 | 9.58 | 8.69 | 9.15 | 9.38 | 8.8 |
Earnings From Equity Investments | -0.18 | - | - | - | - | - |
Currency Exchange Gain (Loss) | -1.91 | 0.26 | -1.04 | 0.58 | 5.85 | -3.76 |
Other Non Operating Income (Expenses) | -15.43 | -2.5 | -3.85 | -9.33 | -1.53 | -6.67 |
EBT Excluding Unusual Items | -98.36 | -95.14 | -163.68 | -113.56 | -32.85 | -29.43 |
Gain (Loss) on Sale of Investments | -0.04 | -0.04 | - | 1.3 | 1.23 | - |
Gain (Loss) on Sale of Assets | - | - | 0.26 | -4.29 | -0.03 | 0.05 |
Asset Writedown | 0.56 | - | -38.4 | -34.17 | - | -2.48 |
Other Unusual Items | -0.28 | 2.03 | 0.96 | 2.2 | 2.31 | 1.17 |
Pretax Income | -98.12 | -93.14 | -200.86 | -148.52 | -29.34 | -30.69 |
Income Tax Expense | 7.65 | 7.97 | -10.36 | -1.23 | -14.41 | -7.65 |
Earnings From Continuing Operations | -105.77 | -101.12 | -190.5 | -147.29 | -14.94 | -23.04 |
Minority Interest in Earnings | -0.76 | -0.59 | -0.17 | -0.13 | 0.29 | 0.28 |
Net Income | -106.53 | -101.71 | -190.67 | -147.42 | -14.65 | -22.76 |
Net Income to Common | -106.53 | -101.71 | -190.67 | -147.42 | -14.65 | -22.76 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 295 | 291 | 289 | 289 | 293 | 285 |
Shares Outstanding (Diluted) | 295 | 291 | 289 | 289 | 293 | 285 |
Shares Change | -3.25% | 0.59% | -0.06% | -1.34% | 2.97% | -0.60% |
EPS (Basic) | -0.36 | -0.35 | -0.66 | -0.51 | -0.05 | -0.08 |
EPS (Diluted) | -0.36 | -0.35 | -0.66 | -0.51 | -0.05 | -0.08 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 14.07 | 17.92 | 50.89 | -50.65 | -114.88 | -296.01 |
Free Cash Flow Per Share | 0.05 | 0.06 | 0.18 | -0.17 | -0.39 | -1.04 |
Gross Margin | 1.98% | 2.38% | -4.80% | 5.63% | 12.40% | 17.92% |
Operating Margin | -14.49% | -13.45% | -23.41% | -15.13% | -4.83% | -3.03% |
Profit Margin | -18.85% | -16.94% | -31.64% | -24.57% | -2.69% | -4.32% |
Free Cash Flow Margin | 2.49% | 2.98% | 8.44% | -8.44% | -21.07% | -56.12% |
EBITDA | -33.12 | -30.71 | -91.01 | -36.5 | 14.86 | 12.87 |
EBITDA Margin | -5.86% | -5.11% | -15.10% | -6.08% | 2.73% | 2.44% |
D&A For EBITDA | 48.82 | 50.04 | 50.04 | 54.27 | 41.22 | 28.88 |
EBIT | -81.94 | -80.75 | -141.05 | -90.77 | -26.36 | -16.01 |
EBIT Margin | -14.49% | -13.45% | -23.41% | -15.13% | -4.83% | -3.03% |
Revenue as Reported | 294.44 | 600.51 | 602.62 | 600.1 | 545.37 | 527.44 |
Advertising Expenses | - | 0.8 | 1.97 | 1.09 | 0.67 | 0.48 |